Edited by: Marc Humbert
The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective
Version of Record online: 10 FEB 2010
© 2010 John Wiley & Sons A/S
Volume 65, Issue 9, pages 1141–1148, September 2010
How to Cite
Campbell, J. D., Spackman, D. E. and Sullivan, S. D. (2010), The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy, 65: 1141–1148. doi: 10.1111/j.1398-9995.2010.02336.x
- Issue online: 4 AUG 2010
- Version of Record online: 10 FEB 2010
- Accepted for publication 05 January 2010
- 11Omalizumab Label; http://www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf .
- 14Risk of Mortality Associated with Asthma Exacerbation. San Diego CA: ATS 2009., , , .
- 15National Heart Lung and Blood Institute. Morbidity and Mortality: 2002 Chartbook on Cardiovascular, Lung, and Blood Diseases. Bethesda, MD: US Department of Health and Human Services; 2002.
- 17Deriving preference- based single indicies from non-preference based condition-specific instruments: converting AQLQ into EQ-5D indices. The University of Sheffield, School of Health and Related Research, Sheffield Health Economics Group Discussion Paper Series 02/1, May 2002. (N = 3880 subject visits)., , , .
- 19Burden of poorly controlled asthma for patients and society in the UK. Prim Care Resp J 2004;13:113., , .
- 20MarketScan Databases 2006. [cited 2007 September 7]; Available from: http://www.medstat.com/products/productdetail.aspx?id=71.
- 21CPT Search. 2009 [cited 3/6/09]; Available from: https://catalog.ama-assn.org/Catalog/cpt/cpt_search.jsp?locality=AA.
- 22Good research practices for measuring drug costs in cost effectiveness and analyses: issues and recommendations: the ISPOR drug cost task force report-Part I. Value Health 2010;13:8–13., , , , , et al.
- 23The Zitter Group. Zitter Managed Care Injectables Index. Fall 2008.
- 24United States Department of Labor Bureau of Labor Statistics. Inflation Calculator.
- 26Evaluating response to omalizumab (anti-IgE) in clinical practice. Poster presented at the European Respiratory Society Meeting, 17–21 September 2005; Copenhagen., , et al.
- 27Cost-Effectiveness in Health and Medicine. New York: Oxford Press Inc, 1996., , , .
- 30Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma: National Heart, Lung, and Blood Institute. national Asthma Education and Prevention Program (NAEPP); 2007.